Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2006-05-23
2006-05-23
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C514S012200, C530S351000, C530S399000
Reexamination Certificate
active
07048922
ABSTRACT:
A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from aplastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 C.F.R. § 1.72(b).
REFERENCES:
patent: 5015664 (1991-05-01), Green
patent: 5047421 (1991-09-01), Green
patent: 5108760 (1992-04-01), Irr et al.
patent: 5506267 (1996-04-01), Aono et al.
patent: 5525232 (1996-06-01), Veiro et al.
patent: 5550161 (1996-08-01), Green
patent: 5616612 (1997-04-01), Ayral-Kaloustian et al.
patent: 5643786 (1997-07-01), Cohen et al.
patent: 5658945 (1997-08-01), Ayral-Kaloustian et al.
patent: 5766920 (1998-06-01), Babbitt et al.
patent: 5932446 (1999-08-01), Gallagher et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6008042 (1999-12-01), Dixit et al.
patent: 6010878 (2000-01-01), Dixit et al.
patent: 6010905 (2000-01-01), Cohen et al.
patent: 6033661 (2000-03-01), Smith et al.
patent: 6187821 (2001-02-01), Fujita et al.
patent: 6203787 (2001-03-01), Thompson et al.
patent: 6294169 (2001-09-01), Dixit et al.
patent: 6340461 (2002-01-01), Terman
patent: 6352694 (2002-03-01), June et al.
patent: 2001/0027215 (2001-10-01), Perrine
patent: 1 077 254 (2001-02-01), None
patent: WO 95/20649 (1995-08-01), None
patent: WO 96/23060 (1996-08-01), None
patent: WO 98/06823 (1998-02-01), None
patent: WO 01/34788 (2001-05-01), None
patent: WO 01/62092 (2001-08-01), None
patent: WO 02/36748 (2002-05-01), None
Brugger et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1beta, IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81: 2579-2584, 1993.
Waclavicek et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Brit J Haematol 114(2): 466-473, 2001.
Chen et al. Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematotherapy and stem cell research 12(5): 505-514, 2003.
Shah et al. Why do we still use serum in the production of biopharmaceuticals? Dev Biol Stand 99: 17-22, 1999.
Lipscomb et al. Dendritic cells: immune regulators in health and disease. Physiol Rev 82: 97-130, 2002.
Dallaporta et al. Plasma membrane potential in thymocyte apoptosis. J Immunol 162: 6534-6542, 1999.
Furlong et al. Induction of apoptosis by valinomycin: mitochondrial permeability transition causes intracellular acidification. Cell Death Different 5: 214-221, 1998.
Gwag et al. Calcium ionophores can induce either apoptosis or necrosis in cultured cortical neurons. Neuroscience. 90(4):1339-1348, 1990.
Sigma Chemical Company Catalog. “Ionophores”, pp. 587-589, 1995.
Calbiochem Catalog. 2000-2001. “Ionophores”, pp. 1, 91, 208, 262, 310, 369, 403, 412, 483, 486, 520, 554, 912.
Bakker et al. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol. 61(1):18-27, 2000.
Aiba et al. Dendritic cell activation induced by various stimuli, e.g. exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix. J Dermatol Sci. 20(1):1-13, 1998.
Xaus et al. Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis. Immunobiology. 204(5):543-550, 2001.
Kamath et al. Platelet activation: assessment and quantification.Eur Heart J. 22(17):1561-1571, 2001.
Stewart et al. Vascular endothelial cell activation in models of vascular and glomerular injury. Kidney Int Suppl. 45:S37-44, 1994.
Erdahl et al. Ca2+ transport properties of ionophores A23187, ionomycin, and 4-BrA23187 in a well defined model system. Biophys J 66: 1676-1693, 1994.
Abramov et al. Actions of ionomycin, 4-BrA23187 and a novel electrogenic Ca2+ ionophore on mitochondria in intact cells. Cell Calcium 33: 101-112, 2003.
Bedrosian et al., “Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Interleukin-12 Synergize With Calcium Ionophore to Enhance Dendritic Cell Function,” Journal of Immunotherophy, May-Jun. 2000, vol. 23, No. 3, pp. 311-320.
Chopra et al., “Interleukin 2, Interleukin 2 Receptor, and Interferon-yamma Synthesis and mNRA Expression in Phorbol Myristate Acetate and Calcium Ionophore A23187-Simulated T Cell From Elderly Humans,” Clinical Immunology and Immunopathology, Nov. 1989, vol. 53, pp. 297-308.
Nobrega et al., “Naturally Activated and Resting T Cells Differ in Their Activation Requirements For Growth and Secretory Activities,” Cellular Immunology, Jan. 1990, vol. 125, No. 1, pp. 120-129.
Rodriguez et al., “Regulation of Apoptosis in Interleukin-3-Dependent Hemopoietic Cells by Interleukin-3 and Calcium,” The EMBO Journal, 1990, vol. 9, pp. 2997-3002.
Cooley et al., “Cytokine Activity after human bone marrow transplantation,” British Journal of Haematology, vol. 73, No. 3, pp. 341-347, 1989.
Czerniecki et al., “Calcium Ionophore-Treated Peripheral Blood Monocytes and Dendritic Cells Rapidly Display Characteristics of Activated Dentritic Cells,” Journal of Immunology, vol. 159, No. 8, pp. 3823-3837, Oct. 15, 1997.
Faries et al., “Calcium Signaling inhibits interleukin-12 production and activates CD83+dendritic cells that induce Th2 cell development,” Blood, vol. 98, No. 8, pp. 2489-2497, Oct. 15, 2001.
Koski et al., “Calcium Ionophore-Treated Myeloid Cells Acquire Many Dendritic Cell Characteristics Independent of Prior Differentiation State, Transformation Status, or Sensitivity to Biologic Agents,” Blood, vol. 94, No. 4, pp. 1359-1371, Aug. 15, 1999.
Roros et al., “Calcium ionophore and cytokine treatment of human peripheral blood myeloid cells produces dendritic cells with an enhanced abaility to sensitize autologous CD8+T cells to tumor antigens in a single culture stimulation,” Proceedings of the annual meeting of the American Association for Cancer Research, New York, NY, vol. 38, pp. 631, Apr. 12, 1997.
Westers et al., “A23187/IL-4 Cultural Leukemic Dendritic Cells Stimulate Autologous T Cell-Mediated Apoptosis of Acute Myeloid Leukemic Blasts,” Blood, vol. 98, No. 11 Part 1, pp. 121a, Nov. 16, 2001.
Bagby, “Production of Multi Lineage Growth Factors by Hematopoietic Stromal Cells: An Intercellular Regulatory Network Involving Mononuclear Phagocytes and Interleukin-1,” Blood Cells, 13, pp. 147-159, 1987.
Champlin et al., “Treatment of Refactory Aplastic Anemia With Recombinant Human Granulocyte-Macrophage-Colony-Stimulating Factor,” Blood, vol. 73, No. 3, pp. 694-699, Feb. 15, 1989.
Ettinghausen et al., “Hematologic Effects of Immunotherapy With Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in Cancer Patients,” Blood, vol. 69, No. 6, pp. 1654-1660, Jun. 1987.
Ferrara et al., “Graft-Versus-Host Disease,” The New England Journal of Medicine, Mechanisms of Disease, vol. 324, No. 10, pp. 667-674, Mar. 7, 1991.
Fibbe et al., “Human Fibroblasts Produce Granulocyte-CSF, Macrophage-CSF, and Granulocyte-Macrophage-CSF Following Stimulation by Interleukin-1 and Poly(R1).Poly(rC),” Blood, vol. 72, No. 3, pp. 860-866, Sep. 1988.
Fujimori et al., “Effect of Lymphokine-Activated Killer Cell Fraction on the Development of Human Hematopoietic Progenitor Cells,” Cancer Res, vol. 48, No. 3, pp. 534-538, Feb. 1, 1988 (abstract only).
Ganser et al., “Effect of Recombinant Human Interleukin-3 in Patients With Normal Hematopoiesis and in Patients With Bone Marrow Failure,” Blood, vol. 6, No. 4, pp
Bunner Bridget E.
Dardi Peter S.
Kemmerer Elizabeth
Patterson Thuente Skaar & Christensen P.A.
LandOfFree
Stimulation of hematopoiesis by ex vivo activated immune cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulation of hematopoiesis by ex vivo activated immune cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulation of hematopoiesis by ex vivo activated immune cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3538744